X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home IPR Data Management

OPTIMA Has Made AstraZeneca And Mutabor Official Partners

Content Team by Content Team
10th October 2022
in IPR Data Management, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have collaborated on the Innovative Medicines Initiative (IMI), which has announced the commencement of the public-private research programme OPTIMA which is defined as Optimal Treatment for Patients & Solid Tumours in Europe Through Artificial Intelligence.

The €21.3 million programme aims to employ AI to enhance treatment for individuals with lung, breast, and prostate cancer. The objective of OPTIMA is to design, create, and deliver the first interoperable, GDPR-compliant real-world oncology information and proof-generating platform in Europe, allowing medical practitioners to offer each patient with solid tumours from the three malignancies the best possible individualised care.

AstraZeneca and MUTABOR are now formally partners in the research, thirteen months after it began. The project’s coordinators, Professor Dr. James N’Dow of the University of Aberdeen’s Academic Urology Unit and the European Association of Urology, and Dr. Hagen Krüger, senior medical director of oncology for Pfizer Germany, are happy that AstraZeneca and MUTABOR are now part of the project consortium. This means that the consortium’s knowledge will grow.

In order to ensure that the initiative is at the forefront of pushing the creation and deployment of individualised patient-centric oncological treatment for prostate, breast, and lung cancer across Europe, Professor N’Dow said that OPTIMA would work with AstraZeneca and MUTABOR.

OPTIMA has accumulated all the resources and knowledge needed to accomplish this; it is now time for them to work jointly in a highly collaborative environment to realise the lofty goals. 

Oncology is one of the diseases for which AstraZeneca will concentrate on the research, development, and commercialization of prescription medications. Additionally, the business will test the data management with various user types and collect suggestions for modifications to help grow the platform.

David Dellamonica, who is in charge of digital and innovation for AstraZeneca’s cancer business in Europe and Canada, released a statement expressing the company’s pleasure upon learning that it has been accepted into the OPTIMA collaboration. Collecting information on actual cancer patients from all around Europe and, more significantly, making use of that knowledge is essential to achieving their common objective of transforming cancer treatment in Europe.

They will boost collaborative decision-making and build standardised, proofed treatment protocols by utilising the latest technologies to acquire practical insights from this large quantity of data. According to what he had previously stated, their ultimate objective is to expand the number of cancer patients who have access to the most recent developments in medical and scientific treatment.

Previous Post

OSD Contract Manufacturing Sector Valued At $54.7bn By 2030

Next Post

RNA Vaccine UK Innovation Centre At CPI Gets Fresh Funding

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

RNA Vaccine UK Innovation Centre At CPI Gets Fresh Funding

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In